Status:

COMPLETED

SPINCOMS Biomarker Study

Lead Sponsor:

Washington University School of Medicine

Collaborating Sponsors:

National Institute of Allergy and Infectious Diseases (NIAID)

University of Colorado, Denver

Conditions:

Multiple Sclerosis

Eligibility:

All Genders

18+ years

Brief Summary

To determine if biomarker-based CSF testing is reliably detecting differences between patients with Multiple Sclerosis (MS), different MS-subtypes, and other central nervous system (CNS) diseases. Thi...

Detailed Description

Using machine learning, the investigators have developed from SOMAScan: 1. A molecular diagnostic test that differentiates MS from other inflammatory and non-inflammatory central nervous system (CNS)...

Eligibility Criteria

Inclusion

  • MS Patients selection criteria
  • Lumbar puncture (LP) in the untreated stage with cryopreserved CSF (serum/blood optional) with consent to use it for future research
  • ≥ 3 and ≤ 10 years of follow-up from LP
  • At time of LP untreated and not treated with steroid or off steroids ≥ one month
  • Available/willing to come for in-person follow-up
  • Available/willing to sign the NIH 09-I-0032 "Sample processing only" consent form
  • Diagnosis of MS based on 2017 McDonald criteria at time of follow-up visit
  • Non-MS Patients selection criteria Required: 25 Non-Inflammatory Neurological Disease (NIND), 25 Other Inflammatory Neurological Disease (OIND)
  • Lumbar puncture (LP) in the untreated stage with cryopreserved CSF (serum/blood optional) with consent to use it for future research
  • ≥ 3 and ≤ 10 years of follow-up from LP
  • At time of LP untreated and not treated with steroid or off steroids ≥ one month
  • Up to date contact information
  • Available/willing to sign the NIH 09-I-0032 "Sample processing only" consent form
  • Diagnosis:
  • NIND: e.g., ischemic-gliotic changes, CADASIL and other leukodystrophies, migraines, ischemic spinal cord lesions etc OIND: e.g. CNS Sjogren's, SLE, vasculitis, CNS infections, MOG-associated disorders, NMO spectrum disorders (NMOSD)

Exclusion

    Key Trial Info

    Start Date :

    June 15 2020

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    November 24 2023

    Estimated Enrollment :

    161 Patients enrolled

    Trial Details

    Trial ID

    NCT04496830

    Start Date

    June 15 2020

    End Date

    November 24 2023

    Last Update

    September 11 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Washington University in St Louis

    St Louis, Missouri, United States, 63110